Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COVID-19 Vaccine, Inactivated · 1 trial · 1 indication
The GMT of neutralizing antibodies 28 days after the second vaccination.
| Arm | Type | Description |
|---|---|---|
| 3-5 years old age group | EXPERIMENTAL | 500 participants aged 3-5 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28. |
| 6-11 years old age group | EXPERIMENTAL | 500 participants aged 6-11 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28. |
| Name | Type | Description |
|---|---|---|
| COVID-19 Vaccine,Inactivated | BIOLOGICAL | The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection |
Inclusion Criteria: * Healthy participants aged 3-11 years; * The participants and/or their guardians are able to understand and sign the informed consent voluntarily (in accordance with the local regulations)(For subjects aged 3-7years ,guardians need to sign the informed consent form,for subjects...
COVID-19 Vaccine, Inactivated is an investigational vaccine being developed for the prevention of COVID-19. It is currently in Phase 3 clinical development and has been studied in healthy populations, including children aged 3 to 11 years, in China.
COVID-19 Vaccine, Inactivated is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company. The company's stock is traded under the ticker symbol SVA.
COVID-19 Vaccine, Inactivated is in Phase 3 clinical development. It is an investigational vaccine and has not been approved for use. A Phase 3 trial has been completed to evaluate its safety and immunogenicity.
COVID-19 Vaccine, Inactivated has been studied in a completed Phase 3 clinical trial with the identifier NCT05137418. This trial assessed the safety and immunogenicity of the vaccine in healthy individuals aged 3 to 11 years in China, enrolling 1,000 participants.
COVID-19 Vaccine, Inactivated is classified as a monoclonal antibody modality, though it is being developed as a vaccine for COVID-19. It is currently in Phase 3 clinical trials and is not yet approved.